scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - scPharmaceuticals reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.30, representing an earnings surprise of -13.33% [1] - The company posted revenues of $16.04 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.19%, compared to revenues of $8.05 million a year ago [2] - Over the last four quarters, scPharmaceuticals has surpassed consensus EPS estimates only once [2] Stock Movement and Outlook - scPharmaceuticals shares have increased by approximately 48.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at -$0.29 for the coming quarter and -$1.04 for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which scPharmaceuticals belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The performance of scPharmaceuticals may also be influenced by the overall industry outlook, as top-ranked industries tend to outperform lower-ranked ones by a significant margin [8]